SARS-CoV-2-IN-110 (compound Bb1) is an inhibitor of SARS-CoV-2, demonstrating antiviral efficacy with an EC50 of 1.10 µM, and significantly reduced toxicity compared to Lapatinib. The compound exhibits a CC50 of greater than 100 µM against SARS-CoV-2, with a selectivity index (SI) exceeding 91.
Molecular Weight:
498.94
Formula:
C28H20ClFN4O2
Target:
SARS-CoV
* VAT and and shipping costs not included. Errors and price changes excepted
